Prostate-Specific Membrane Antigen

An investigational targeted radioligand therapy improved outcomes for certain men with advanced prostate cancer, according to randomized phase 3 study results to be presented during the plenary session of the virtual ASCO Annual Meeting.

The FDA approved piflufolastat F 18 injection, a radioactive diagnostic agent designed to identify suspected metastasis or recurrence of prostate cancer, according to the agent’s manufacturer.